2-(dodecylthio)-5-phenyl-1,3,4-oxadiazole | 1321878-21-0

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-(dodecylthio)-5-phenyl-1,3,4-oxadiazole
• 英文别名: 2-Dodecylsulfanyl-5-phenyl-1,3,4-oxadiazole
• CAS: 1321878-21-0
• 化学式: C₂₀H₃₀N₂OS
• 分子量: 346.537
• InChiKey: NKZBSAIIAWRNQC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.8
• 重原子数：
  24
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  64.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-苯基-1,3,4-恶二唑-2-硫醇 在 hexaammonium heptamolybdate tetrahydrate 、 双氧水 、 三乙胺 作用下， 以 四氢呋喃 、 aq. phosphate buffer 、 乙醇 为溶剂， 反应 5.0h， 生成 2-(dodecylthio)-5-phenyl-1,3,4-oxadiazole
  参考文献：
  名称：

  使用 Julia-Kocieński 样试剂快速、稳定、化学选择性标记硫醇：一种血清稳定的马来酰亚胺基蛋白质缀合替代品

  摘要：

  已发现在各种缓冲条件下甲基磺酰基苯基恶二唑化合物对半胱氨酸具有精确的化学选择性。此外，所得到的蛋白质偶联物比人血浆中的半胱氨酸-马来酰亚胺偶联物（HSA=人血清白蛋白，MBP-C-HA=麦芽糖结合蛋白）具有更好的稳定性。这种新的硫醇点击反应为生成稳定的蛋白质偶联物和聚乙二醇化蛋白质提供了一种新方法。

  DOI：

  10.1002/anie.201306241

文献信息

• Copper-catalyzed direct thiolation of azoles with aliphatic thiols
  作者：An-Xi Zhou、Xue-Yuan Liu、Ke Yang、Shu-Chun Zhao、Yong-Min Liang

  DOI：10.1039/c1ob05395g

  日期：——

  Cu(II)-catalyzed direct thiolation of azoles with thiols is described via intermolecular C–S bond formation/C–H functionalization under oxidative conditions. Both aryl thiols and aliphatic thiols are used as coupling partners, and furnished the thiolation products in moderate to good yields. The reaction is compatible with a wide range of heterocycles including oxazole, thiazole, imidazole and oxadiazole.

  报道了在氧化条件下通过分子间C-S键形成/C-H官能化，铜(II)催化的硫醇与含氮杂环的直接硫化反应。使用芳基硫醇和脂肪族硫醇作为偶联伴侣，并以中等到良好的产率得到硫化产物。该反应适用于包括噁唑、�iaz唑、咪唑和噁二唑等多种杂环。
• COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS
  申请人：THE BROAD INSTITUTE, INC.

  公开号：US20160031870A1

  公开（公告）日：2016-02-04

  Disclosed are compounds that can be used for treating tuberculosis.

  本发明涉及用于治疗结核病的化合物。
• Compounds for the treatment of tuberculosis
  申请人：THE BROAD INSTITUTE, INC.

  公开号：US10301294B2

  公开（公告）日：2019-05-28

  Disclosed are compounds that can be used for treating tuberculosis.

  所公开的是可用于治疗结核病的化合物。
• HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9
  申请人：AMGEN, INC.

  公开号：EP2968985A2

  公开（公告）日：2016-01-20
• [EN] HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9<br/>[FR] PROTÉINES DE LIAISON À UN ANTIGÈNE HUMAIN SE LIANT À LA PROPROTÉINE CONVERTASE SUBTILISINE KEXINE DE TYPE 9
  申请人：AMGEN INC

  公开号：WO2014144080A2

  公开（公告）日：2014-09-18

  The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inhibiting PCSK9 binding to LDLR and having increased pH sensitivity, improved binding affinity and/or increased in vivos half life. In embodiments, the antigen binding proteins specifically bind PCSK9 and have increased pH sensitivity, improved binding affinity and/or increased in vivos half life. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind PCSK9 Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from hypercholesterolemia and related disorders or conditions.